ASXL Symposium Series - Part V

ASXL1 is essential for stem cell functions

AЯRE ASXL Conference 2018, UCLA Los Angeles - Feng-Chun Yang, M.D./Ph.D.:

Identify the molecular targets and develop novel therapeutics for ASXL1mutation –associated diseases - part 1

AЯRE ASXL Conference 2018, UCLA Los Angeles - Feng-Chun Yang, M.D./Ph.D.:

Identify the molecular targets and develop novel therapeutics for ASXL1mutation –associated diseases - part 2

AЯRE ASXL Conference 2018, UCLA Los Angeles - Feng-Chun Yang, M.D./Ph.D.:

Identify the molecular targets and develop novel therapeutics for ASXL1mutation –associated diseases - part 3

Dr. Yang is an established investigator in the field of stem cell biology and myeloid malignancies. She is a Professor of Biochemistry and Molecular Biology at the University of Miami, where her area of research is in molecular mechanisms involved in Genetic Disease and Cancer. 

Dr. Yang has been studying the cellular and molecular mechanisms underlying the pathogenesis of BOS and myeloid malignancies.  The ultimate goal of her research is to identify novel therapeutic targets and to develop rational therapies to treat myeloid malignancies and BOS.  She has authored over 90 peer-reviewed papers in the field of research and is a member of several professional societies.  Dr. Yang also serves on the review boards for numerous professional journals and funding agencies.